Hypertension Clinical Trial
Official title:
Boxing Training Effects on Cardiovascular Risk, Quality of Life, Endothelial Function, and Blood Flow Patterns in Individuals With Elevated Blood Pressure or Stage 1 Hypertension
Verified date | May 2024 |
Source | University of Texas, El Paso |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical trial is to determine whether boxing training reduces cardiovascular risk in elevated blood pressure or hypertension stage 1 individuals. The main questions it aims to answer are (1) if boxing training reduces peripheral and central blood pressure and (2) if boxing training improves cardiovascular function in elevated blood pressure or hypertension stage 1 individuals. Participants with elevated blood pressure or hypertension stage 1 will be randomly divided into a control group or an intervention group. The latter group will be involved in boxing training, 3 days per week for 6 weeks. Researchers will compare clinical and cardiovascular outcomes between the control and the intervention group.
Status | Completed |
Enrollment | 24 |
Est. completion date | March 15, 2020 |
Est. primary completion date | March 15, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - =18 years old. - Systolic blood pressure between 120-139 mmHg and/or diastolic blood pressure between 80-89 mmHg obtained from 2 different days. - an estimated 10-year risk of CVD =10%, calculated by the ACC/AHA Pooled Cohort Equations. - no current participation in 3 or more days per week of endurance or resistance exercise training. Exclusion Criteria: - non-controlled cardiac, pulmonary, or metabolic diseases. - smoking, consumption of nutritional supplements containing antioxidants. - any physical impairment to exercise. |
Country | Name | City | State |
---|---|---|---|
United States | The University of Texas at El Paso | El Paso | Texas |
Lead Sponsor | Collaborator |
---|---|
University of Texas, El Paso |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline brachial blood pressure after week six | Resting systolic and diastolic blood pressure (mmHg) | pre-intervention and immediately after the intervention | |
Secondary | Central Blood Pressure | Pulse wave analysis (mmHg) | pre-intervention and immediately after the intervention | |
Secondary | Vascular function | Flow mediated dilation (%) | pre-intervention and immediately after the intervention | |
Secondary | Plethysmography | Forearm and Calf Blood Flow (ml/min/100 ml tissue) | pre-intervention and immediately after the intervention | |
Secondary | Maximum Oxygen Uptake | Cardiopulmonary Test (ml/kg/min) | pre-intervention and immediately after the intervention | |
Secondary | Nitric Oxide Bioavailability | Blood Biomarker NOx (µmol/L) | pre-intervention and immediately after the intervention | |
Secondary | Body Fat Percentage | Dual energy x-ray absorptiometry Scan to assess Body Fat % | pre-intervention and immediately after the intervention | |
Secondary | Lean Mass | Dual energy x-ray absorptiometry Scan to assess lean mass (kg) | pre-intervention and immediately after the intervention | |
Secondary | Quality of Life measured by the short-form 36 (SF-36) | The short form 36 (SF-36) is a short survey that covers a total of 8 sub-dimensions related to physical and mental health: (1) Physical Functioning, (2) Role Limitations due to Physical Problems, (3) Social Functioning, (4) Bodily Pain, (5) General Mental Health, (6) Role Limitations due to Mental Problems, (7) Vitality, and (8) General Health Perceptions. The SF-36 includes a diverse mixture of continuous item scaling methods and is comprised of 10 items with balanced multi-item response formats (range from 1 to 5), 7 items with a dichotomous response format (1 or 2), and 19 items with non-balanced multi-item response formats (nine items range from 1 to 3 and ten items range from 1 to 6). To obtain the raw score for each sub-dimension, 10 items are reversed. Then, raw values for each sub-dimension are summed. Finally, the raw scores are transformed to a 0-to-100 scale for each sub-dimension. Higher scores indicate higher Quality of Life from 0 (worst) to 100 (best). | pre-intervention and immediately after the intervention | |
Secondary | Arterial Stiffness | Pulse wave velocity from carotid to femoral artery (m/s) | pre-intervention and immediately after the intervention | |
Secondary | C Reactive Protein (CRP) to assess inflammation | Blood Biomarker CRP (mg/L) | pre-intervention and immediately after the intervention | |
Secondary | Interleukin-6 (IL-6) to assess inflammation | Blood Biomarker IL-6 (pg/ml) | pre-intervention and immediately after the intervention | |
Secondary | Tumor necrosis factor alfa (TNFa) to assess inflammation | Blood Biomarker TNFa (pg/ml) | pre-intervention and immediately after the intervention | |
Secondary | 8-isoprostane to assess inflammation | Blood Biomarker 8-isoprostane (pg/ml) | pre-intervention and immediately after the intervention | |
Secondary | Superoxide dismutase (SOD) to assess oxidative stress | Blood Biomarker SOD (mU/ml) | pre-intervention and immediately after the intervention | |
Secondary | Total Antioxidant Capacity (TAC) to assess oxidative stress | Blood Biomarker TAC (mM/ml) | pre-intervention and immediately after the intervention | |
Secondary | Lipid Profile | Blood Biomarkers HDL-C, LDL-C, and total cholesterol (mg/dl) | pre-intervention and immediately after the intervention | |
Secondary | Weight | Weight in kilograms | pre-intervention and immediately after the intervention | |
Secondary | Height | Height in meters | pre-intervention and immediately after the intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |